Interview with Jan Egberts, CEO, OctoPlus N.V.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Address: Zernikedreef 12, 2333 CL Leiden,Netherlands
Tel: +31 (0)71 524 40 44
OctoPlus is a product-oriented drug delivery company focused on the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. Since our inception in 1995, we have established a successful track record and maintain partnerships with large and small biotech and pharma companies throughout the world.
Our business activities include formulation development services, drug delivery technologies and controlled release product development.
OctoPlus uses its proprietary drug delivery technologies to develop controlled release products for clients.
OctoPlus has developed a number of proprietary drug delivery technologies that facilitate the controlled release of biologically active compounds. Our three main technology platforms enable us to develop tailor-made controlled release formulations for all classes of injectable drug compounds:
OctoDEX®: a dextran-based microsphere delivery technology for proteins and particulate systems.
PolyActive®: a biodegradable polymeric drug delivery system for the controlled release of proteins and lipophilic small molecules.
SynBiosys™: a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules (in collaboration with Innocore BV).
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here
